Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05889156 · ClinicalTrials.gov registry record · Phase 2
Study of the Efficacy and Safety of NST-1024 Versus Placebo in Subjects With Hypertriglyceridemia
A Phase 2 study, sponsored by NorthSea Therapeutics B.V..
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT05889156 is a Phase 2 study that has completed, run by NorthSea Therapeutics B.V.. The registered enrollment target is 50 participants.
The verdict
NCT05889156, a Phase 2 study, has completed, sponsored by NorthSea Therapeutics B.V..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
This is a Phase IIa,multicentre proof of concept study consisting of 2 study periods to study Treatment with NST-1024 as an adjunct to diet to reduce triglyceride (TG) levels in subjects with TG levels of ≥500 mg/dL and ≤2000 mg/dL; determined by percentage change in TG from baseline after 28 days of treatment. The two periods consist of: 1. A 3-week screening period that includes a TG qualifying period, and 2. A 28-days, double-blind, randomized, parallel group, placebo-controlled treatment period. Subjects will return to the study site for a follow-up visit 2 weeks after the last dose. Approximately 50 subjects will be randomized at approximately 15-35 centers in USA.
Interventions
- OTHER Placebo
- DRUG NST-1024
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-06-30 |
| Est. Completion | 2025-04-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05889156
The ClinicalTrials.gov registry entry for NCT05889156 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NorthSea Therapeutics B.V., which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05889156 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05889156 about?
NCT05889156 is a clinical study titled "Study of the Efficacy and Safety of NST-1024 Versus Placebo in Subjects With Hypertriglyceridemia". This is a Phase IIa,multicentre proof of concept study consisting of 2 study periods to study Treatment with NST-1024 as an adjunct to diet to reduce triglyceride (TG) levels in subjects with TG levels of ≥500 mg/dL and ≤2000 mg/dL; determined by percentage change in TG from baseline after 28 days o...
What is the current status of trial NCT05889156?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2023-06-30. Estimated completion is 2025-04-11.
What interventions are being tested in trial NCT05889156?
The interventions under investigation include: Placebo (OTHER), NST-1024 (DRUG).
Who is sponsoring clinical trial NCT05889156?
This trial is sponsored by NorthSea Therapeutics B.V., which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.